Cargando...
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies demonstrated that PCSK9 binds to the low-density lipoprotein (LDL) receptor directing it to its lysosomal degradation. Therefore, ca...
Gardado en:
| Publicado en: | Front Physiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7701092/ https://ncbi.nlm.nih.gov/pubmed/33304274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2020.595819 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|